ESMO Breast 2023 | ADCs in early breast cancer

Sung-Bae Kim, MD, PhD, Asan Medical Center, Seoul, Korea, comments on how the use of antibody-drug conjugates is now being explored in early disease, neo-adjuvant, and residual disease settings, after being recognized as a safe and effective therapy in metastatic breast cancer. This interview took place at the 2023 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress in Berlin, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.